On June 30, 2023, Eton Pharmaceuticals, Inc. terminated its Asset Purchase Agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation, where it intended to acquire pharmaceutical products for $34-$37 million but was not the successful bidder, and received a break-up fee of $800,000.